The Guideline Development Group for the Management of Breakthrough Pain will be starting their data collection in May 2022 using the Survey Monkey format. The audit will focus on patients who have used breakthrough medication, including any immediate release fentanyl products in the preceding 12 months.

They would like everyone to start thinking now about how best to identify patients who have used these products in this timeframe or who may be currently using them. Starting a list now should make it so much easier to then submit sufficient cases when the survey goes live and of course receive that important localised report. The more data we can provide for the GDG the more useful the audit will be

If you do have any queries please contact chair@pallaborative.org.uk and we will forward on messages to the Guideline Development Group.